topic

182 Highly potent fully human anti-VISTA antibodies – a new target checkpoint inhibitor against immunosuppressive myeloid cells
Thierry Guillaudeux, Eric Tarcha, Robert Bader, Benjamin Dutzar, Nathan Eyde, Emily Frazier, David Jurchen, Remington Lance, Cristina Loomis, Kurt Lustig, Yulia Ovechkina, David Peckham, Shaarwari Sridhar, Mei Xu, Shawn Iadonato, Thierry Guillaudeux, Jeff Posakony

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A108; DOI: 10.1136/jitc-2020-SITC2020.0182
185 Camrelizumab monotherapy or combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma:a retrospective study
Hong Liu, Shuhuai Niu, Zhaohui Fang, Xi Chen, Qianying Zhang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A109-A110; DOI: 10.1136/jitc-2020-SITC2020.0185
184 Two types of anti-TIGIT antibodies with distinct binding epitope and functional activities
Tingting Zhong, Xinghua Pang, Zhaoliang Huang, Na Chen, Xiaoping Jin, Yu Xia, Maxwell Zhongmin Wang, Baiyong Li

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A109; DOI: 10.1136/jitc-2020-SITC2020.0184
186 Distinct immune signatures predicting clinical response to PD-1 blockade therapy in gynecological cancers revealed by high-dimensional immune profiling
Yuki Muroyama, Yuki Muroyama, Sasikanth Manne, Alexandar Huang, Divij Mathew, Lakshmi Chilukuri, Allison Greenplate, Takuya Ohtani, Dmitriy Zamarin, Claire Friedman, John Wherry

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A110; DOI: 10.1136/jitc-2020-SITC2020.0186
187 Real-world treatment patterns and clinical predictors of overall survival among anti-PD-1 exposed advanced melanoma patients with documented evidence of disease progression
Cathy Anne Pinto, Xinyue Liu, Xiaoyun Li, Emilie Scherrer, Mizuho Kalabis

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A110-A111; DOI: 10.1136/jitc-2020-SITC2020.0187
188 Novel Anti-SIRpalpha antibodies with differentiated characteristics as promising cancer therapeutics
Minu K Srivastava, Ryan Alvarado, Sushma Krishnan, Christine Tan, Swati Jalgaonkar, George Huang, Erin L Filbert, Frances R Bahjat, Xiaodong Yang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A111; DOI: 10.1136/jitc-2020-SITC2020.0188
190 Timing of steroid doses and response rates to immune-checkpoint inhibitors in metastatic cancer
Karine Tawagi, Diana Maslov, Victoria Simenson, Helen Yuan, Cameron Parent, Adi Bamnolker, Richa Goel, Zoe Blake, KC Madhav, Marc Matrana, Karine Tawagi, Daniel Johnson, Karine Tawagi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A112; DOI: 10.1136/jitc-2020-SITC2020.0190
191 Association of immune related adverse events with the efficacy of immune checkpoint inhibitors in metastatic renal cell carcinoma
Vasilii Bushunow, Leonard Appleman, Roby Thomas

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A112-A113; DOI: 10.1136/jitc-2020-SITC2020.0191
192 ‘Immune-brain’: a case series of cognitive dysfunction/decline in cancer patients on immunotherapy
Sarah Gillett, Ximena Jordan-Bruno, Hibba Rehman, Alissa Thomas, Sarah Gillett

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A113-A114; DOI: 10.1136/jitc-2020-SITC2020.0192
194 A multicenter characterization of chronic toxicities following adjuvant anti-PD-1 therapy for high risk resected melanoma
James Patrinely, Rebecca Johnson, Aleigha Lawless, Prachi Bhave, Amelia Sawyers, Maya Dimitrova, Hui Yeohc, Marisa Palmeri, Elizabeth Davis, Suthee Rapisuwon, Georgina Long, Andrew Haydon, Iman Osman, Janice Mehnert, Matteo Carlino, Ryan Sullivan, Alexander Menzies, Douglas Johnson

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A114-A115; DOI: 10.1136/jitc-2020-SITC2020.0194

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages